Registered title, quoted from ClinicalTrials.gov
NK Cell Therapy for Malignant Solid Brain Tumors
An open trial on glioma, registered on ClinicalTrials.gov. Led by Peking University Third Hospital; 1 other hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 2
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Lead sponsorPeking University Third Hospital北京大学第三医院BeijingHospital page
- Study siteZhengzhou Second HospitalZhengzhouHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07552233, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 8
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (8 points)Hide the checklist
18 years to 70 years; sex: all
Registered eligibility fields
At least one evaluable lesion with previous biopsy or pathohistologic confirmation of malignant central nervous system tumor, with imaging suggestive of continued progression or recurrence after comprehensive treatment
Inclusion criterion 2
Patients who completed radiotherapy or systemic therapies (including temozolomide/bevacizumab or other agents) for at least 4 weeks prior to enrollment. All prior treatment-related toxicities should be defined as ≤ grade 1 (except for toxicities such as alopecia or leukoplakia) according to the Common Terminology Standard for Adverse Events (CTCAE 6.0)
Inclusion criterion 5
Fertile women must have had a pregnancy test with a negative result within 7 days prior to the start of treatment, and subjects are willing to use contraception (hormonal or barrier method of birth control or abstinence) during the clinical trial and for 6 months after the last cell infusion; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately
Inclusion criterion 20
Karnofsky Performance Status (KPS) ≥ 60%
Inclusion criterion 3
White blood cell count (WBC) ≥ 3 x 10\^9/L
Inclusion criterion 8
Absolute neutrophil count (ANC) > 1 x 10\^9/L
Inclusion criterion 9
Hemoglobin (Hb) ≥ 90 g/L
Inclusion criterion 10
Platelet (PLT) ≥ 80×10\^9/L
Inclusion criterion 11
Albumin transaminase (ALT) \& albumin transaminase (AST) < 1.5 × institutional upper limit of normal (ULN)
Inclusion criterion 12
Serum creatinine (Cr) < 1.5 x institutional ULN
Inclusion criterion 13
Total bilirubin < 1.5 x institutional ULN
Inclusion criterion 14
PT \& PTT ≤ 1.25 x institutional ULN
Inclusion criterion 15
Life expectancy > 4 weeks, and must be able to undergo an MRI with contrast
Inclusion criterion 4
Active hepatitis B or C virus, HIV infection, or other untreated active infection
Exclusion criterion 1
Pregnant and lactating women
Exclusion criterion 2
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07552233, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Male or female, age 18-70 years old (both ends included)
- At least one evaluable lesion with previous biopsy or pathohistologic confirmation of malignant central nervous system tumor, with imaging suggestive of continued progression or recurrence after comprehensive treatment
- Karnofsky Performance Status (KPS) ≥ 60%
- Life expectancy > 4 weeks, and must be able to undergo an MRI with contrast
- Patients who completed radiotherapy or systemic therapies (including temozolomide/bevacizumab or other agents) for at least 4 weeks prior to enrollment. All prior treatment-related toxicities should be defined as ≤ grade 1 (except for toxicities such as alopecia or leukoplakia) according to the Common Terminology Standard for Adverse Events (CTCAE 6.0)
- Dexamethasone dose ≤ 4 mg/day or equivalent corticosteroid dose, or no dexamethasone administered
- Must have adequate organ and marrow function as defined below:
- White blood cell count (WBC) ≥ 3 x 10\^9/L
- Absolute neutrophil count (ANC) > 1 x 10\^9/L
- Hemoglobin (Hb) ≥ 90 g/L
- Platelet (PLT) ≥ 80×10\^9/L
- Albumin transaminase (ALT) \& albumin transaminase (AST) < 1.5 × institutional upper limit of normal (ULN)
- Serum creatinine (Cr) < 1.5 x institutional ULN
- Total bilirubin < 1.5 x institutional ULN
- PT \& PTT ≤ 1.25 x institutional ULN
- No obvious hereditary diseases
- Normal cardiac function with left ventricular ejection fraction >55%
- No bleeding and coagulation disorders
- Absence of positive blood cultures for bacteria, fungus, or virus within 48-hours prior to NK cell infusion and/or there aren't any indications of meningitis
- Fertile women must have had a pregnancy test with a negative result within 7 days prior to the start of treatment, and subjects are willing to use contraception (hormonal or barrier method of birth control or abstinence) during the clinical trial and for 6 months after the last cell infusion; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately
- Signed, written informed consent
Exclusion Criteria:
- Active hepatitis B or C virus, HIV infection, or other untreated active infection
- Pregnant and lactating women
- Participants with organ failure
- Participants with a chronic disease requiring immunologic or hormonal therapy
- Participants with an allergy to immunotherapy and related cells
- Participants with uncontrolled intercurrent illness
- Participants with psychiatric illness/social situations that would limit compliance with study requirements
- Participants with a history of organ transplantation or who are awaiting organ transplantation
Quoted from ClinicalTrials.gov, NCT07552233, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07552233, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.